Amgen Inc. (AMGN)
Amgen: Time For An Upgrade? Yes, I Think So
Amgen Inc. is upgraded to a cautious Buy, reflecting improved fundamentals, a diversified pipeline, and a decent risk/reward profile despite recent underperformance versus the S&P. Key growth drivers include Imdelltra, Uplizna, Tepezza, Repatha, and the promising but unproven Maritide, offsetting declines from legacy drugs like Prolia. AMGN's robust R&D pipeline, margin expansion, and capital investments are positioning the company for sustained long-term growth, though high debt and capex warrant monitoring.
Amgen Touts MariTide, AI Gains and 2026 Growth Plans at Jefferies Conference
Amgen NASDAQ: AMGN executives used a Jefferies investor conference appearance to emphasize the company's first-quarter growth, its late-stage pipeline and its preparations for potential launches, including the obesity candidate MariTide.
Amgen Inc. (AMGN) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Amgen Inc. (AMGN) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Amgen Secures EU Nod for Imdylltra in Lung Cancer Indication
AMGN wins EU approval for Imdylltra in extensive-stage small cell lung cancer after phase III data showed a 40% reduction in death risk.
Here's Why Amgen (AMGN) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
This Boring Income Portfolio Strategy Could Unlock 300%+ Upside
Most people think you can't time the market. That's nonsense.
Novo Nordisk vs. Amgen: Which Pharma Stock Is the Better Buy?
NVO and AMGN square off as GLP-1 leadership, pipeline depth and diversification shape a compelling healthcare stock comparison.
AMGN Stock Down 13% in 3 Months: Buy the Dip or Book Profits?
Amgen faces LOE headwinds and pricing pressure, yet key growth drugs and biosimilars continue gaining traction.
Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know
Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Amgen's Growth Engine Is Just Getting Started
Amgen delivers consistent, market-beating returns, supported by a robust growth portfolio and prudent capital allocation. AMGN's pipeline strength is evident, with 16 drugs on track for blockbuster status and promising new assets like MariTide in obesity. At a forward P/E of 15.1 and 3% yield, AMGN offers an attractive blend of income and growth, justifying a continued ‘Buy' rating.
Doctors in Japan can again prescribe an Amgen rare-disease drug to new patients, reversing a recommendation made only days ago following 20 deaths
The Japanese drugmaker that sells rare-disease medicine Tavneos said new patients will be able to get the drug, which carries risk of liver injury.
Twenty people in Japan who took an Amgen rare immune-disease drug have died, according to the company that sells the medicine in Japan. U.S. drug regulators had asked Amgen to voluntarily withdraw the drug.
Kissei Pharmaceutical, which sells the rare immune-disease drug in Japan, warned doctors to stop prescribing it to new patients.
